Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6Genitourinary 4Thoracic 3Gastrointestinal 3Breast 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Azacitidine 41Cytarabine 27fludarabine phosphate 25Cyclophosphamide 23venetoclax 21fludarabine 21Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 17Filgrastim 17Decitabine 17Tacrolimus 16Whole-Body Irradiation 15ruxolitinib 14Cyclosporine 14Busulfan 14Melphalan 12Methotrexate 10Imatinib Mesylate 10Stem Cell Transplantation 9Antilymphocyte Serum 8Alemtuzumab 8nilotinib 7decitabine and cedazuridine drug combination 7Granulocyte Colony-Stimulating Factor 7Rituximab 6Injections 6Idarubicin 6Dasatinib 6Clofarabine 6AP 1903 reagent 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × rucaparib × Myeloid × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡